Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 16-Feb-24 9:48 PM View:  | Desrosier Thomas Chief Legal Officer and EVP | Seres Therapeutics, Inc. (MCRB) | 16-Feb-24 | Planned Option Sale | 3,939 | $1.08 | $4,254.12 | (3%) 124.52K to 120.58K | |
| 16-Feb-24 9:15 PM View: | Ege David S. See Remarks | Seres Therapeutics, Inc. (MCRB) | 16-Feb-24 | Planned Option Sale | 5,010 | $1.08 | $5,410.80 | (6%) 78.87K to 73.86K | |
| 16-Feb-24 9:42 PM View: | Shaff Eric D. CEO and President Director | Seres Therapeutics, Inc. (MCRB) | 16-Feb-24 | Planned Option Sale | 11,549 | $1.08 | $12,472.90 | (8%) 146.87K to 135.32K | |
| 16-Feb-24 9:31 PM View: | Henn Matthew R. See Remarks | Seres Therapeutics, Inc. (MCRB) | 16-Feb-24 | Planned Option Sale | 4,170 | $1.08 | $4,503.60 | (6%) 67.61K to 63.44K | |
| 16-Feb-24 9:21 PM View: | von Moltke Lisa See Remarks | Seres Therapeutics, Inc. (MCRB) | 16-Feb-24 | Planned Option Sale | 4,400 | $1.08 | $4,752.00 | (21%) 21.39K to 16.99K | |
| 16-Feb-24 9:13 PM View: | Arkowitz David Chief Financial Officer | Seres Therapeutics, Inc. (MCRB) | 16-Feb-24 | Planned Option Sale | 3,939 | $1.08 | $4,254.12 | (2%) 186.38K to 182.44K | |
| 16-Feb-24 9:29 PM View: | Young Teresa L. See Remarks | Seres Therapeutics, Inc. (MCRB) | 16-Feb-24 | Planned Option Sale | 3,374 | $1.08 | $3,643.92 | (18%) 19.08K to 15.71K | |
| 16-Feb-24 9:31 PM View: | Henn Matthew R. See Remarks | Seres Therapeutics, Inc. (MCRB) | 15-Feb-24 | Option Exercise | 11,250 | -- | -- | 20% 56.36K to 67.61K | |
| 16-Feb-24 9:21 PM View: | von Moltke Lisa See Remarks | Seres Therapeutics, Inc. (MCRB) | 15-Feb-24 | Option Exercise | 11,875 | -- | -- | 125% 9.51K to 21.39K | |
| 16-Feb-24 9:13 PM View: | Arkowitz David Chief Financial Officer | Seres Therapeutics, Inc. (MCRB) | 15-Feb-24 | Option Exercise | 10,625 | -- | -- | 6% 175.76K to 186.38K | |
| 16-Feb-24 9:29 PM View: | Young Teresa L. See Remarks | Seres Therapeutics, Inc. (MCRB) | 15-Feb-24 | Option Exercise | 10,625 | -- | -- | 126% 8.45K to 19.08K | |
| 16-Feb-24 9:48 PM View: | Desrosier Thomas Chief Legal Officer and EVP | Seres Therapeutics, Inc. (MCRB) | 15-Feb-24 | Option Exercise | 10,625 | -- | -- | 9% 113.89K to 124.52K | |
| 16-Feb-24 9:15 PM View: | Ege David S. See Remarks | Seres Therapeutics, Inc. (MCRB) | 15-Feb-24 | Option Exercise | 11,875 | -- | -- | 18% 66.99K to 78.87K | |
| 16-Feb-24 9:42 PM View: | Shaff Eric D. CEO and President Director | Seres Therapeutics, Inc. (MCRB) | 15-Feb-24 | Option Exercise | 31,250 | -- | -- | 27% 115.62K to 146.87K | |
| 31-Oct-23 9:43 PM View: | Cloghessy Paula See Remarks | Seres Therapeutics, Inc. (MCRB) | 30-Oct-23 | Planned Option Sale | 2,904 | $1.35 | $3,920.40 | (6%) 48.59K to 45.68K | |
| 31-Oct-23 9:40 PM View: | Young Teresa L. See Remarks | Seres Therapeutics, Inc. (MCRB) | 30-Oct-23 | Planned Option Sale | 2,907 | $1.35 | $3,924.45 | (26%) 11.36K to 8.45K | |
| 31-Oct-23 9:39 PM View: | Desrosier Thomas Chief Legal Officer and EVP | Seres Therapeutics, Inc. (MCRB) | 30-Oct-23 | Planned Option Sale | 4,156 | $1.35 | $5,610.60 | (4%) 118.05K to 113.89K | |
| 31-Oct-23 9:39 PM View: | Ege David S. See Remarks | Seres Therapeutics, Inc. (MCRB) | 30-Oct-23 | Planned Option Sale | 4,066 | $1.35 | $5,489.10 | (6%) 71.06K to 66.99K | |
| 31-Oct-23 9:40 PM View: | Shaff Eric D. CEO and President Director | Seres Therapeutics, Inc. (MCRB) | 30-Oct-23 | Planned Option Sale | 8,552 | $1.35 | $11,545.20 | (7%) 124.17K to 115.62K | |
| 31-Oct-23 9:36 PM View: | Henn Matthew R. See Remarks | Seres Therapeutics, Inc. (MCRB) | 30-Oct-23 | Planned Option Sale | 3,886 | $1.35 | $5,246.10 | (6%) 60.24K to 56.36K | |
| 31-Oct-23 9:36 PM View: | von Moltke Lisa See Remarks | Seres Therapeutics, Inc. (MCRB) | 30-Oct-23 | Planned Option Sale | 4,232 | $1.35 | $5,713.20 | (31%) 13.74K to 9.51K | |
| 31-Oct-23 9:39 PM View: | Arkowitz David Chief Financial Officer | Seres Therapeutics, Inc. (MCRB) | 30-Oct-23 | Planned Option Sale | 4,066 | $1.35 | $5,489.10 | (2%) 179.82K to 175.76K | |
| 31-Oct-23 9:40 PM View: | Shaff Eric D. CEO and President Director | Seres Therapeutics, Inc. (MCRB) | 27-Oct-23 | Option Exercise | 27,838 | -- | -- | 29% 96.33K to 124.17K | |
| 31-Oct-23 9:36 PM View: | Henn Matthew R. See Remarks | Seres Therapeutics, Inc. (MCRB) | 27-Oct-23 | Option Exercise | 12,623 | -- | -- | 27% 47.62K to 60.24K | |
| 31-Oct-23 9:36 PM View: | von Moltke Lisa See Remarks | Seres Therapeutics, Inc. (MCRB) | 27-Oct-23 | Option Exercise | 13,745 | -- | -- | 100% 0 to 13.74K | |
| 31-Oct-23 9:39 PM View: | Arkowitz David Chief Financial Officer | Seres Therapeutics, Inc. (MCRB) | 27-Oct-23 | Option Exercise | 13,209 | -- | -- | 8% 166.61K to 179.82K | |
| 31-Oct-23 9:43 PM View: | Cloghessy Paula See Remarks | Seres Therapeutics, Inc. (MCRB) | 27-Oct-23 | Option Exercise | 9,418 | -- | -- | 24% 39.17K to 48.59K | |
| 31-Oct-23 9:40 PM View: | Young Teresa L. See Remarks | Seres Therapeutics, Inc. (MCRB) | 27-Oct-23 | Option Exercise | 11,361 | -- | -- | 100% 0 to 11.36K | |
| 31-Oct-23 9:39 PM View: | Desrosier Thomas Chief Legal Officer and EVP | Seres Therapeutics, Inc. (MCRB) | 27-Oct-23 | Option Exercise | 13,501 | -- | -- | 13% 104.55K to 118.05K | |
| 31-Oct-23 9:39 PM View: | Ege David S. See Remarks | Seres Therapeutics, Inc. (MCRB) | 27-Oct-23 | Option Exercise | 11,361 | -- | -- | 19% 59.7K to 71.06K | |
| 01-May-23 4:46 PM View: | Ege David S. See Remarks | Seres Therapeutics, Inc. (MCRB) | 28-Apr-23 | Sale (Planned) | 7,038 | $5.19 | $36,527.20 | (11%) 66.73K to 59.7K | |
| 01-May-23 4:43 PM View: | Arkowitz David Chief Financial Officer | Seres Therapeutics, Inc. (MCRB) | 27-Apr-23 | Grant | 42,500 | -- | -- | 34% 124.11K to 166.61K | |
| 01-May-23 4:46 PM View: | Ege David S. See Remarks | Seres Therapeutics, Inc. (MCRB) | 27-Apr-23 | Grant | 20,000 | -- | -- | 43% 46.73K to 66.73K | |
| 31-Oct-22 7:37 PM View: | Ege David S. See Remarks | Seres Therapeutics, Inc. (MCRB) | 31-Oct-22 | Sale (Planned) | 5,012 | $7.93 | $39,745.20 | (10%) 51.75K to 46.73K | |
| 31-Oct-22 7:37 PM View: | Ege David S. See Remarks | Seres Therapeutics, Inc. (MCRB) | 27-Oct-22 | Grant | 20,000 | -- | -- | 63% 31.75K to 51.75K | |
| 31-Oct-22 6:05 PM View: | Arkowitz David Chief Financial Officer | Seres Therapeutics, Inc. (MCRB) | 27-Oct-22 | Grant | 42,500 | -- | -- | 60% 70.49K to 112.99K | |
| 07-Jul-22 5:00 PM View: | Nutritional Health Ltp Fund... 10% Owner | Seres Therapeutics, Inc. (MCRB) | 05-Jul-22 | Private Purchase | 8,738,240 | $3.15 | $27,525,500.00 | 59% 14.75M to 23.49M | |
| 06-Jul-22 7:27 PM View: | Henn Matthew R. See Remarks | Seres Therapeutics, Inc. (MCRB) | 05-Jul-22 | Grant | 47,619 | $3.15 | $150,000.00 | 100% 0 to 47.62K | |
| 06-Jul-22 7:19 PM View: | Biondi Paul Director | Seres Therapeutics, Inc. (MCRB) | 05-Jul-22 | Grant | 47,619 | $3.15 | $150,000.00 | 100% 0 to 47.62K | |
| 06-Jul-22 7:22 PM View: | Ege David S. See Remarks | Seres Therapeutics, Inc. (MCRB) | 05-Jul-22 | Grant | 31,746 | $3.15 | $99,999.90 | 100% 0 to 31.75K | |
| 06-Jul-22 7:22 PM View: | Dere Willard H Director | Seres Therapeutics, Inc. (MCRB) | 05-Jul-22 | Grant | 31,746 | $3.15 | $99,999.90 | 100% 0 to 31.75K | |
| 06-Jul-22 7:25 PM View: | Cloghessy Paula See Remarks | Seres Therapeutics, Inc. (MCRB) | 05-Jul-22 | Grant | 31,746 | $3.15 | $99,999.90 | 100% 0 to 31.75K | |
| 06-Jul-22 7:23 PM View: | Arkowitz David Chief Financial Officer | Seres Therapeutics, Inc. (MCRB) | 05-Jul-22 | Grant | 63,492 | $3.15 | $200,000.00 | 3175% 2.0K to 65.49K | |
| 06-Jul-22 7:29 PM View: | Desrosier Thomas Chief Legal Officer and EVP | Seres Therapeutics, Inc. (MCRB) | 05-Jul-22 | Grant | 63,492 | $3.15 | $200,000.00 | 155% 41.05K to 104.55K | |
| 06-Jul-22 7:21 PM View: | Shaff Eric D. CEO and President Director | Seres Therapeutics, Inc. (MCRB) | 05-Jul-22 | Grant | 63,492 | $3.15 | $200,000.00 | 193% 32.84K to 96.33K | |
| 06-Jul-22 7:19 PM View: | Zausner Meryl Director | Seres Therapeutics, Inc. (MCRB) | 05-Jul-22 | Grant | 31,746 | $3.15 | $99,999.90 | 100% 0 to 31.75K | |
| 06-Jul-22 7:23 PM View: | Kender Richard N Director | Seres Therapeutics, Inc. (MCRB) | 05-Jul-22 | Grant | 63,492 | $3.15 | $200,000.00 | 100% 0 to 63.49K | |
| 31-Oct-22 6:05 PM View: | Arkowitz David Chief Financial Officer | Seres Therapeutics, Inc. (MCRB) | 15-Jun-22 | Option Exercise | 5,000 | -- | -- | 8% 65.49K to 70.49K | |
| 19-May-21 7:05 PM View: | Nutritional Health Ltp Fund... 10% Owner | Seres Therapeutics, Inc. (MCRB) | 17-May-21 | Disposition (other) | 295,171 | -- | -- | (2%) 15.05M to 14.75M | |
| 03-Dec-20 4:05 PM View: | Henn Matthew R. See Remarks | Seres Therapeutics, Inc. (MCRB) | 01-Dec-20 | Option Exercise | 79,812 | $5.56 | $443,720.00 | 665% 12.0K to 91.81K |
